# Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma

> **NCT05449366** · PHASE1,PHASE2 · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Peritoneal Malignant Mesothelioma

## Interventions

- **DRUG:** Intraperitoneal Paclitaxel Solution (Ml)

## Key facts

- **NCT ID:** NCT05449366
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05449366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05449366, "Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05449366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*